Volume 15, Issue 5 (September & October 2024)
BCN 2024, 15(5): 583-594 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghasempour S, Maghsoudi N, Manaheji H, Ghasemi R, Jaafarisuha A, Zaringhalam J. A New Dipeptide H-MGL Partially Ameliorating Memory Impairment in an STZ-induced Alzheimer Model in Male Rats. BCN 2024; 15 (5) :583-594
URL: http://bcn.iums.ac.ir/article-1-2721-en.html
URL: http://bcn.iums.ac.ir/article-1-2721-en.html
Sarieh Ghasempour1 
, Nader Maghsoudi2 , Homa Manaheji1 , Rasoul Ghasemi1 , Ali Jaafarisuha1 , Jalal Zaringhalam * 1
, Nader Maghsoudi2 , Homa Manaheji1 , Rasoul Ghasemi1 , Ali Jaafarisuha1 , Jalal Zaringhalam * 1
1- Department of Physiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Neurobiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Neurobiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Introduction: Alzheimer disease (AD) is a progressive neurodegenerative disorder that is identified by the gradual decline in memory and cognitive function. It is classified by the deposition of Aβ plaques, the build-up of intracellular neurofibrillary tangle (NFT), and neuron loss. Neurotrophic factors play a critical role in the treatment of AD. However, utilizing such neurotrophins has encountered certain difficulties and side effects. Novel technological advancements prioritize innovative dipeptide usage, which offers fewer side effects.
Methods: The present study endeavors to analyze the compound hexamethylenediamide bis-(N-monosuccinyl-glutamyl-lysine) (lab name: H-MGL), a newly discovered neurotrophin mimetic dipeptide, to alleviate memory impairment in an intracerebroventricular single dose streptozotocin (STZ)-induced Alzheimer model in rats. We arranged 4 groups: Sham and groups receiving STZ and STZ + H-MGL (1 and 2 mg/kg). The H-MGL was administered consecutively for 14 days following the STZ injection. Then, the Morris water maze test was performed.
Results: The findings suggest that administration of STZ caused a significantly increment in mean escape latency and mean traveled distance in acquisition days. H-MGL at a 1 mg/kg dosage failed to yield any notable improvement in rats compared to STZ. By contrast, 2 mg/kg of H-MGL dosage led to a significant decrease in the latency to first platform crossing and frequency of platform crossings.
Conclusion: Consequently, the findings above have engendered the notion that H-MGL partially ameliorates cognitive impairment, so it may hold promise for having low side effects to alleviate cognitive deficits in AD or potentially decrease the symptoms associated with its progression.
Methods: The present study endeavors to analyze the compound hexamethylenediamide bis-(N-monosuccinyl-glutamyl-lysine) (lab name: H-MGL), a newly discovered neurotrophin mimetic dipeptide, to alleviate memory impairment in an intracerebroventricular single dose streptozotocin (STZ)-induced Alzheimer model in rats. We arranged 4 groups: Sham and groups receiving STZ and STZ + H-MGL (1 and 2 mg/kg). The H-MGL was administered consecutively for 14 days following the STZ injection. Then, the Morris water maze test was performed.
Results: The findings suggest that administration of STZ caused a significantly increment in mean escape latency and mean traveled distance in acquisition days. H-MGL at a 1 mg/kg dosage failed to yield any notable improvement in rats compared to STZ. By contrast, 2 mg/kg of H-MGL dosage led to a significant decrease in the latency to first platform crossing and frequency of platform crossings.
Conclusion: Consequently, the findings above have engendered the notion that H-MGL partially ameliorates cognitive impairment, so it may hold promise for having low side effects to alleviate cognitive deficits in AD or potentially decrease the symptoms associated with its progression.
Keywords: Alzheimer disease (AD), Dipeptide, hexamethylenediamide bis-(N-monosuccinyl-glutamyl-lysine) (H-MGL), Escape latency, Latency to first
Type of Study: Original |
Subject:
Behavioral Neuroscience
Received: 2023/05/30 | Accepted: 2023/06/15 | Published: 2024/09/1
Received: 2023/05/30 | Accepted: 2023/06/15 | Published: 2024/09/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
